NKTR Drug delivery Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company

NKTR 56.31

+0.6%

11:42 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (419)	10/2/2018 3:55:45 PM
From: Miljenko Zuanic	of 507

One think that concern me very much about NK-214 is from P1 presentation:..10-fold increase in CTLA-4 gene expression!!?? So, initial (or premature) pseudo-progression of the subject is melanoma-expansion cohort (and RCC), (generating mediocre response rate of <20%) may be explained on CTLA-4/PD-1 hypothesis. Unfortunately, many subject that have PD were lost in (discontinued) trial and results may/will not be pleasurably. Only protein/Tcells-TIL expressions profile in tumor samples from cancer subjects, without any concern on the validity of such data, may stimulate BMY to continue NK-214 development. Melanoma P3 is a good start, but trial is "SLOW TO START"? Any problem from BMY side??????

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next